Spot on notrex. It might not have been possible for Alan to grab that cash at 95p, but it demonstrated retail demand at that level. When the price was 120p, a fundraise for retail at 95p would have potentially raised more at far less dilution. The money I used to 'top up' at 70p would have gone straight in their bank account. Never mind though, Alan's mates got a good deal.
NY, doesn’t matter who leaked it. Company or participants, the end result is the same. In the past we’ve seen the placing price named. This time it does look like it wasnt pre-determined so we were on a hiding to as low as possible with mugs like me getting a ‘bargain’ at 70p.
Should have been at over £2 according to the broker that’s on the payroll, not a quid. I would question that they’ve managed to obtain any qualitative funding as it’s lost in the roundings of the share register. Shafting PIs to reduce their overall percentage by raising ant 50p hasn’t achieved much, it was only 20% dilution. Alan has a few more mates n the register at small amounts. So what.
Good posts though.
"STS is rare. About 3,300 cases per year are reported in the United Kingdom,2 and 13,500 new cases were reported in the United States in 2021, with 5,300 deaths, for an incidence rate of 15 to 35 per 1 million of the adult population."
https://www.ccjm.org/content/89/2/73
Given the usual appalling comms we've no idea what's really going. The 'delay' could be recruitment and there's no way to fast track that. They're focussed in a particular area - you don't get ODD for common stuff. So there won't be a readily available pool of people with the particular cancer they're interested in, having been treated previously in a particular way that are willing to sign up for a trial in a particular group of hospitals. It's not difficult to imagine that numbers are small. Yeah, we could flog it / licence it (ink well is still full) and BP could run the trial in more sites, but it's not getting to market overnight, you can't shortcut trials. We can see that from the 1b phase (now named as "leading up to P2") that's reappeared in the (nonsense) timelines from nowhere (thanks for the comms Al).
Bella, they're not moaning, they're trolls. Although a thread titled disappointment does hint at some moaning - but that was aimed at Alan and fully deserved. He hates PIs and it shows. The reason is because he gets asked awkward questions that make him and his ever changing embarrassment of a strategy look like the shambolic mess it is.
The science looks good, they have cash, the trial crawls on - it'll take as long as it takes and if it takes longer they'll just rip off PIs again. Let's wait a year or two and see where we are.
It’ll be a quick debate in parliament, the FCA already have the power to ban short selling. That petition is pointless.
‘The SSR gives us the power to apply short or long-term bans on short sales in shares, and certain other financial instruments. ’
https://www.fca.org.uk/markets/short-selling/statement-short-selling-bans-and-reporting
The sealion was correct that they needed money. That’s because a dribbling idiot that’s just finished his latest brown crayon masterpiece on the wall knew that. Probably best to dispel any myth that there was any kind of genius in stating the absolute obvious that this business burns cash. It’s part of the MO, spout the obvious and then use that to proclaim you’re the all seeing eye to give a semblance of truth to the accompanying BS. Mix it in a 2000 word essay, throw in 17 questions and bingo, you’ve got yourself a troll sealion that in reality hasn’t a clue. His track record is the only truth worth paying attention to.
'Business people employ scientists, it shouldn’t be the other way around'
Beautiful.
Simple as that. Alan is naïve. He doesn't know what he's doing. That's not unfair, it's a fact. He's never led a clinical stage company, he done a great job getting it this far. Pat on the back, have a few more options... Now leave Alan. It's got more potential than a lifestyle business. Let someone who knows what they're doing take charge.
My view is they should keep it if it brings in decent cash. I don’t subscribe to the Myles McTwatty view of flogging it off at a loss. My view is that it was a terrible decision in the first place and compounding that by making a second bad decision doesn’t help. It looked like combined they should bring in about £6m pa ebitda. With the expansion in to Germany that was touted - more BS Alan? - they could have a decent business on their hands for once.